Gecko Biomedical Selected To Participate In TEDMED’s “Hive” In November 2015

PARIS--(BUSINESS WIRE)--Gecko Biomedical, a French medical device company developing innovative polymers in the form of sealants and adhesives for wound closure, announces that the company has been selected to take part in TEDMED’s “Hive” in November 2015 in Palm Springs, California. Aligning with this year’s event’s theme “Breaking Through to a Healthier Tomorrow”, Maria Pereira, Head of Research, will represent the company and discuss its innovative technologies being designed to improve post-surgical healing and patient recovery.

“We are very excited and proud to have been selected to take part in this year’s Hive, alongside such remarkable start-ups and entrepreneurs. At Gecko Biomedical, we strive to provide patients with improved care and better quality of life, and are eager to continue working towards a healthier tomorrow.”

Christophe Bancel, Chief Executive Officer and co-founder of Gecko Biomedical, commented: “We are very excited and proud to have been selected to take part in this year’s Hive, alongside such remarkable start-ups and entrepreneurs. At Gecko Biomedical, we strive to provide patients with improved care and better quality of life, and are eager to continue working towards a healthier tomorrow.”

Maria Pereira, Ph.D., is Head of Research, responsible for the adhesive products pipeline and for the translation of the core technologies from the academic to the industrial settings. Maria holds a PharmD degree from the University of Coimbra and a PhD in bioengineering systems within the MIT-Portugal framework.
Maria was named on the 2014’s “35 Innovators Under 35” list by MIT Technology Review. She was also recognized by Forbes Magazine in its 2015 “30 under 30” selection in Healthcare.

About TEDMED
TEDMED is the independently owned and operated health and medicine edition of the world-famous TED conference, dedicated to “ideas worth spreading.” TED Talks have been viewed online over two billion times around the world.
Created by TED’s founder, TEDMED convenes and curates extraordinary people and ideas from all disciplines both inside and outside of medicine in pursuit of unexpected connections that accelerate innovation in health and medicine. Best known for their annual event, TEDMED is a year-round global community.

About The Hive
Exciting innovations are challenging the status quo across health and medicine in areas like biotech, health IT, mHealth, life sciences, health tech, and more. TEDMED celebrates the ideas behind this progress in a program called The Hive, which is dedicated to celebrating the power of imagination and human potential that emerges from our collective, “hive” mind. Transformative startups and the inspiring entrepreneurs that power them are an important part of the TEDMED community and conversation. This year at TEDMED 2015, The Hive companies and their leaders will be integrated within the community activities and the larger stage program for a more collaborative experience.

For more information about TEDMED 2015, please visit the event web site.

About Gecko Biomedical
Gecko Biomedical is a privately owned medical device company based in Paris, France that is dedicated to the rapid development and the commercialization of innovative polymers in the form of sealants and adhesives for surgical wound closure. Gecko Biomedical’s polymers are non-toxic, bind strongly to tissues and deliver ‘on-demand’ wound closure within the ‘wet’ and dynamic environments in the body. The company is expected to start clinical trials for its first product “GB02” in vascular reconstruction, towards the end of 2015. Gecko Biomedical is also working on expanding its versatile polymer platform to various tissues and to other applications, while leveraging the significant regulatory milestones achieved with GB02. The Company’s technologies are based on world-class research and intellectual property from the laboratories of Robert Langer (MIT) and Jeff Karp (Brigham and Women’s Hospital). Gecko Biomedical was founded in 2013 and is backed by leading healthcare investors Omnes Capital, CM-CIC and CapDecisif Management.